Murray; Christopher K.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Murray; Christopher K..The latest application filed is for "crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt".

Company Profile

3.15.11

Murray; Christopher K. - Lexington MA
Murray; Christopher K. - Longmont CO
Murray; Christopher K. - Boulder CO

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,384,086 - Murray , et al. July 12, 2	2022-07-12
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,279,705 - Murray , et al. March 22, 2	2022-03-22
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,192,896 - Murray , et al. December 7, 2	2021-12-07
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,192,897 - Murray , et al. December 7, 2	2021-12-07
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 11,192,895 - Murray , et al. December 7, 2	2021-12-07
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210340149 - Murray; Christopher K. ; et al.	2021-11-04
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210277012 - Murray; Christopher K. ; et al.	2021-09-09
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210277011 - Murray; Christopher K. ; et al.	2021-09-09
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210277010 - Murray; Christopher K. ; et al.	2021-09-09
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide And Its Mono Hydrochloride Salt App 20210024527 - Murray; Christopher K. ; et al.	2021-01-28
Crystalline forms of 3-(imidazo[1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 10,662,197 - Murray , et al.	2020-05-26
Crystalline Forms Of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl App 20190169196 - Murray; Christopher K. ; et al.	2019-06-06
Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(- trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 10,125,136 - Murray , et al. November 13, 2	2018-11-13
Crystalline Forms Of 3-(imidazo[1,2-b] Pyridazin-3-ylethynyl)-4-methyl-n-benzamide And Its Mono Hydrochloride Salt App 20170190707 - Murray; Christopher K. ; et al.	2017-07-06
Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Grant 9,493,470 - Murray , et al. November 15, 2	2016-11-15
Crystalline Forms Of 3-(imidazo[1,2-b] Pyridazin-3-ylethynyl)-4-methyl-n-benzamide And Its Mono Hydrochloride Salt App 20150315194 - Murray; Christopher K. ; et al.	2015-11-05
7-hexanolytaxol and methods for preparing the same Grant 6,753,345 - Murray , et al. June 22, 2	2004-06-22
7-hexanolytaxol and methods for preparing the same App 20030083367 - Murray, Christopher K. ; et al.	2003-05-01
Disulfides and thiol compounds Grant 6,414,114 - Taub , et al. July 2, 2	2002-07-02
Low Molecular Weight Cell, Bone Marrow And Immune Stimulants App 20020035118 - TAUB, FLOYD ; et al.	2002-03-21
Novel Disulfides And Thiol Compounds App 20010008933 - TAUB, FLOYD E. ; et al.	2001-07-19
Cephalomannine epoxide, its analogues and a method for preparing the same Grant 5,892,063 - Zheng , et al. April 6, 1	1999-04-06
Preparation of Taxol and docetaxel through primary amines Grant 5,808,113 - Murray , et al. September 15, 1	1998-09-15
Selective process for the deacylation and deacetylation of taxol and taxanes Grant 5,629,433 - Zheng , et al. May 13, 1	1997-05-13
Cytotoxic agents Grant 5,356,928 - Murray , et al. October 18, 1	1994-10-18
Oxidation products of cephalomannine Grant 5,336,684 - Murray , et al. August 9, 1	1994-08-09

Company Registrations

SEC

0001718648

Murray Christopher K.

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.